Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ARNT
REST API REST API
Homo sapiens
ARNT is differentially expressed in 302 experiments: 150 organism parts: hypothalamus, liver, ... (148 more);, 204 disease states: normal, control, ... (202 more);, 86 cell types 431 cell lines 48 compound treatments and 83 other conditions.
Synonyms HIF-1beta, bHLHe2
Orthologs Q95KW4_BOVIN (Bos taurus)   Q4H3W4_CIOIN (Ciona intestinalis)   arnt (Danio rerio)   Arnt (Rattus norvegicus)   Q98SN3_CHICK (Gallus gallus)   Arnt (Mus musculus)   tgo (Drosophila melanogaster)   arnt (Xenopus laevis)   ARNT (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, protein binding, regulation of transcription, DNA-dependent, cytoplasm, transcription, DNA-dependent, response to hypoxia, signal transducer activity, transcription factor binding, cell differentiation, mRNA transcription from RNA polymerase II promoter, sequence-specific DNA binding, positive regulation of transcription from RNA polymerase II promoter, transcription coactivator activity, nucleus, protein heterodimerization activity, transcription factor complex, signal transduction, positive regulation of transcription, DNA-dependent, positive regulation of erythrocyte differentiation, positive regulation of glycolysis, aryl hydrocarbon receptor binding, aryl hydrocarbon receptor activity, regulation of transcription from RNA polymerase II promoter in response to oxidative stress, positive regulation of vascular endothelial growth factor receptor signaling pathway, positive regulation of protein sumoylation, positive regulation of endothelial cell proliferation, positive regulation of hormone biosynthetic process, positive regulation vascular endothelial growth factor production, embryonic placenta development, sequence-specific DNA binding transcription factor activity, sequence-specific distal enhancer binding RNA polymerase II transcription factor activity
InterPro Term PAC, PAS, PAS_fold_3, Nuc_translocat, PAS_fold, HLH_DNA-bd
UniProt Accession P27540, D6RDB3, C9J0D7, Q59ED4, A6NGV6, E7EN08, F8WAP6, F8T0U4, F8T0U3
Search EB-eye ENSG00000143437
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (44 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081, E-GEOD-5823
HL-60
3
E-GEOD-24147, E-MTAB-37, E-GEOD-5258
MDA-MB-231
3
E-TABM-420, E-MTAB-62, E-GEOD-5823
A549
2
E-GEOD-6013, E-GEOD-3202
SW480
2
E-MEXP-1014, E-MTAB-37
U87
2
E-GEOD-20089, E-MEXP-903
425 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, ... (44 experiments)

Factor Value U/D Experiments
mononuclear cell
2
E-MEXP-66, E-GEOD-6053
macrophage
2
E-GEOD-5099, E-GEOD-22373
2
2
E-TABM-145, E-TABM-130
mononuclear
2
E-GEOD-13987, E-GEOD-26672
monocyte
1
2
E-GEOD-11755, E-MEXP-583, E-GEOD-22373
CD16+ dendritic cell
1
E-TABM-34
80 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-16363, E-MTAB-62, ... (69 experiments)

Factor Value U/D Experiments
control
5
E-GEOD-21912, E-GEOD-16363, E-GEOD-8121, E-GEOD-20295, E-GEOD-20602 ... (5 experiments)
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
acute quadriplegic myopathy
2
E-MTAB-62, E-GEOD-3307
AIDS-KS, HIV+, nodular (late) stage
2
2
E-MEXP-66, E-MTAB-62
cervical carcinoma
2
E-MTAB-62, E-GEOD-5823
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
198 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-1417, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (29 experiments)

Factor Value U/D Experiments
none
4
6
E-GEOD-5824, E-MEXP-1958, E-TABM-782, E-MEXP-1601, E-GEOD-412, ... (10 experiments)
control
2
E-GEOD-3284, E-GEOD-4006
ethanol
2
E-MEXP-2241, E-GEOD-3113
lipopolysaccharide
2
E-MEXP-1958, E-GEOD-3720
unknown
1
E-GEOD-7307
AMP
1
1
E-MEXP-2285
42 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd4
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-1563, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-GEOD-4667, E-MEXP-2283, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-7788, E-TABM-147, E-GEOD-21138, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-GEOD-1045, E-GEOD-17476, E-GEOD-2466, E-GEOD-3624, E-GEOD-22593, ... (15 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-12773, E-TABM-127, E-GEOD-20540, E-GEOD-20504, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-MEXP-1648, ... (41 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-MEXP-561, E-GEOD-17400

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7540, E-GEOD-7307, E-GEOD-16363 ... (5 experiments)

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-23984, E-GEOD-11428 ... (5 experiments)

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-15799 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor size
studied in E-GEOD-3494

Vehicle
studied in E-GEOD-5258

Processing time: 0.295 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM